Loading…
Employees: 42
Size Egetis Therapeutics (EGTX.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $528M, the 171st largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 11.12 on 6 Nov 2026.
Performance Over six months the shares gained 66.7%, against -16.1% for the median peer and +8.2% for the Sweden market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 39.5% over the last twelve months (peer median +9.4%); the operating margin is -603.9% (peer median 10.0%).
Valuation It trades at 14.9× forward earnings against a peer median of 19.5× (3rd cheapest of 6).
Capital Return on invested capital runs 190.8 points below its cost of capital (6.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 66.1M | SEK 62.4M | SEK 46.1M | SEK 57.6M | SEK 22.6M |
| Revenue growth | — | +35% | -20% | +155% | — |
| Gross profit | SEK 21.2M | SEK 12.4M | SEK 34.5M | -SEK 127M | -SEK 60.7M |
| EBITDA | n/a | -SEK 343M | -SEK 324M | -SEK 317M | -SEK 194M |
| Net income | -SEK 406M | -SEK 342M | -SEK 344M | -SEK 327M | -SEK 194M |
| Free cash flow | -SEK 301M | -SEK 268M | -SEK 228M | -SEK 278M | -SEK 174M |
| Capital expenditure | SEK 1.00M | SEK 1.50M | SEK 0 | SEK 0 | SEK 0 |
| Total debt | SEK 68.8M | SEK 85.0M | SEK 117M | SEK 113M | SEK 2.70M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EGTX.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.9% | -11.6% | 3rd highest of 21 |
| 6-month return | +66.7% | -16.1% | 3rd highest of 21 |
| Distance from 52-week high | -0.4% | -34.1% | highest of 21 |
| Revenue growth (TTM) | +39.5% | +9.4% | 2nd highest of 20 |
| Operating margin | -603.9% | 10.0% | lowest of 18 |
| Forward P/E | 14.9× | 19.5× | 3rd cheapest of 6 |
| ROIC minus cost of capital | -190.8 pp | -2.6 pp | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 14.9× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | n/a | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 11.1× | -8.9% | +12.6% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 21.6× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | n/a | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | n/a | 17.7% | +4.4% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | n/a | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 19.5× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | n/a | 6.7% | -4.1% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | n/a | -5.2% | +9.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 9.3× | -12.5% | +11.1% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | n/a | -3.9% | +7.6% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 75.5× | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | n/a | n/a | n/a |